IL2 and acute myeloid leukemia: In addition, a clinical trial (NCT01347996) demonstrated a notable decrease in peripheral M-MDSCs among AML patients treated with histamine dihydrochloride (HDC) and low-dose IL-2 for relapse prevention, heralding a promising clinical outcome (146).